Published in J Immunol on August 15, 2006
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 2.70
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum (2012) 2.21
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol (2009) 1.55
The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol (2012) 1.49
Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol (2009) 1.40
BAFF and selection of autoreactive B cells. Trends Immunol (2011) 1.36
Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum (2008) 1.22
Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.21
Lupus nephritis: lessons from murine models. Nat Rev Rheumatol (2009) 1.18
Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol (2008) 1.15
Role of T cells and dendritic cells in glomerular immunopathology. Semin Immunopathol (2007) 1.08
B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol (2011) 1.08
BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol (2011) 1.06
Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum (2010) 1.05
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity (2010) 0.98
B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol (2013) 0.97
Immune opsonins modulate BLyS/BAFF release in a receptor-specific fashion. J Immunol (2008) 0.96
Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis. J Exp Med (2013) 0.94
Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol (2013) 0.93
B-cell activating factor targeted therapy and lupus. Arthritis Res Ther (2012) 0.92
BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res (2011) 0.91
Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum (2013) 0.87
The receptor tyrosine kinase MerTK regulates dendritic cell production of BAFF. Autoimmunity (2009) 0.87
Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice. Arthritis Rheumatol (2014) 0.85
What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol (2015) 0.84
BAFF mediates splenic B cell response and antibody production in experimental Chagas disease. PLoS Negl Trop Dis (2010) 0.84
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther (2015) 0.81
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther (2015) 0.80
Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther (2010) 0.80
Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol (2008) 0.79
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther (2015) 0.78
Apoptotic Debris Accumulates on Hematopoietic Cells and Promotes Disease in Murine and Human Systemic Lupus Erythematosus. J Immunol (2016) 0.77
The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to man. Arthritis Res Ther (2015) 0.76
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. Drug Des Devel Ther (2017) 0.75
BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis. J Immunol (2017) 0.75
A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells. Eur J Immunol (2017) 0.75
Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study. Arthritis Rheumatol (2017) 0.75
A plaque assay for all cells secreting Ig of a given type or class. Eur J Immunol (1976) 9.11
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol (2002) 6.85
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (2001) 5.73
Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity (2002) 4.87
BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (2001) 4.79
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 4.42
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 4.00
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol (2001) 3.87
Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains. Nat Genet (1997) 3.85
A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med (1999) 3.74
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum (2001) 3.72
Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol (2001) 3.65
Regulation of the T-independent humoral response by TACI. Immunity (2001) 3.43
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood (2001) 3.39
Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A (2000) 3.37
TACI and BAFF-R mediate isotype switching in B cells. J Exp Med (2005) 3.31
Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med (2000) 3.00
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest (2003) 2.87
Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol (2001) 2.85
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 2.75
NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science (1997) 2.75
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol (2001) 2.75
BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med (2000) 2.69
The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med (1994) 2.61
TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol (1999) 2.61
Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A (2004) 2.57
B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol (2004) 2.54
TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol (2004) 2.51
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum (2003) 2.47
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum (2003) 2.47
Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem (1999) 2.41
G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med (2003) 2.31
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol (2000) 2.29
Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med (2003) 2.20
APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol (2000) 2.19
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol (2002) 2.16
APRIL modulates B and T cell immunity. J Clin Invest (2002) 2.07
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol (1998) 1.95
Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm Genome (1996) 1.90
Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med (2003) 1.85
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med (2000) 1.83
Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem (2000) 1.72
The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res (1994) 1.72
EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol (2003) 1.70
Differential effects of interleukin-4 in peptide induced autoimmunity. Clin Immunol (2003) 1.62
Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol (2003) 1.54
Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol (2004) 1.53
Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol (2004) 1.53
Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol (2001) 1.49
T cell costimulation by the TNF ligand BAFF. J Immunol (2001) 1.47
BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur J Immunol (2004) 1.44
NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol (2001) 1.42
Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest (1993) 1.38
NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol (2003) 1.38
BAFF augments certain Th1-associated inflammatory responses. J Immunol (2005) 1.37
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther (2006) 1.36
BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum (2005) 1.33
Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol (2003) 1.30
BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol (2004) 1.29
Enforced bcl-xL gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J Immunol (2003) 1.21
Peritoneal and splenic B-1 cells are separable by phenotypic, functional, and transcriptomic characteristics. Eur J Immunol (2004) 1.20
The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol (2004) 1.08
B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J Immunol (2005) 1.08
B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J Immunol (2004) 1.06
Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies. J Immunol (1987) 1.01
Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem (1999) 0.99
B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination. Am J Respir Cell Mol Biol (2005) 0.97
A peptide DNA surrogate accelerates autoimmune manifestations and nephritis in lupus-prone mice. J Immunol (2002) 0.83
MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol (2004) 0.80
The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science (2002) 13.86
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Dev Cell (2008) 5.58
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
Attenuated cold sensitivity in TRPM8 null mice. Neuron (2007) 4.73
Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science (2005) 4.58
Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature (2007) 4.54
Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One (2006) 3.91
White Collar-1, a circadian blue light photoreceptor, binding to the frequency promoter. Science (2002) 3.85
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet (2013) 3.83
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A (2007) 3.24
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol (2010) 3.15
White collar-1, a DNA binding transcription factor and a light sensor. Science (2002) 2.97
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol (2006) 2.96
Characterization of the apical papilla and its residing stem cells from human immature permanent teeth: a pilot study. J Endod (2008) 2.95
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest (2003) 2.87
Practical reconstruction method for bioluminescence tomography. Opt Express (2005) 2.83
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet (2004) 2.66
Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. Nat Med (2010) 2.65
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum (2008) 2.63
LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci (2005) 2.61
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A (2007) 2.60
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum (2009) 2.58
A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun (2005) 2.55
B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol (2004) 2.54
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett (2007) 2.43
TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron (2005) 2.39
Pure spinal epidural cavernous hemangioma. Acta Neurochir (Wien) (2012) 2.38
Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol (2009) 2.37
Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest (2005) 2.36
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog (2009) 2.36
TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med (2008) 2.33
A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol (2006) 2.27
TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol (2006) 2.25
A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clin Rheumatol (2011) 2.24
Diverse pathways generate microRNA-like RNAs and Dicer-independent small interfering RNAs in fungi. Mol Cell (2010) 2.23
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum (2012) 2.21
Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum (2003) 2.21
Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med (2003) 2.20
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum (2006) 2.17
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
Non-optimal codon usage affects expression, structure and function of clock protein FRQ. Nature (2013) 2.15
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res (2012) 2.10
Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. EMBO J (2007) 2.07
Regulation of the Neurospora circadian clock by an RNA helicase. Genes Dev (2004) 2.07
qiRNA is a new type of small interfering RNA induced by DNA damage. Nature (2009) 2.06
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One (2012) 2.01
Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. J Gastroenterol (2015) 2.01
CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol (2004) 2.00
Biocompatible copper(I) catalysts for in vivo imaging of glycans. J Am Chem Soc (2010) 1.98
Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol (2012) 1.97
Phosphorylation of extracellular signal-regulated kinase in primary afferent neurons by noxious stimuli and its involvement in peripheral sensitization. J Neurosci (2002) 1.96
The hidden treasure in apical papilla: the potential role in pulp/dentin regeneration and bioroot engineering. J Endod (2008) 1.95
B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol (2004) 1.93
FWD1-mediated degradation of FREQUENCY in Neurospora establishes a conserved mechanism for circadian clock regulation. EMBO J (2003) 1.89
Molecular mechanism of light responses in Neurospora: from light-induced transcription to photoadaptation. Genes Dev (2005) 1.89
Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) (2010) 1.88
QIP, a putative exonuclease, interacts with the Neurospora Argonaute protein and facilitates conversion of duplex siRNA into single strands. Genes Dev (2007) 1.88
DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites. Biotechniques (2010) 1.88
The Neurospora crassa circadian clock. Adv Genet (2007) 1.86
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood (2007) 1.85
CKI and CKII mediate the FREQUENCY-dependent phosphorylation of the WHITE COLLAR complex to close the Neurospora circadian negative feedback loop. Genes Dev (2006) 1.85
The COP9 signalosome regulates the Neurospora circadian clock by controlling the stability of the SCFFWD-1 complex. Genes Dev (2005) 1.83
PAS domain-mediated WC-1/WC-2 interaction is essential for maintaining the steady-state level of WC-1 and the function of both proteins in circadian clock and light responses of Neurospora. Mol Cell Biol (2002) 1.82
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol (2002) 1.77
Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol (2012) 1.74
TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J (2006) 1.73
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol (2013) 1.72
A radiopathological classification of dural tail sign of meningiomas. J Neurosurg (2012) 1.69
IkappaBbeta acts to inhibit and activate gene expression during the inflammatory response. Nature (2010) 1.68
The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog (2013) 1.67
Increasing the efficacy of bioorthogonal click reactions for bioconjugation: a comparative study. Angew Chem Int Ed Engl (2011) 1.66
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res (2012) 1.65
Convergent antibody signatures in human dengue. Cell Host Microbe (2013) 1.64
R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. Gastroenterology (2007) 1.64
Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol (2006) 1.63
Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance. Arthritis Rheum (2007) 1.62
eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res (2012) 1.62
Differential effects of interleukin-4 in peptide induced autoimmunity. Clin Immunol (2003) 1.62
Non-optimal codon usage is a mechanism to achieve circadian clock conditionality. Nature (2013) 1.61
Targeted disruption of the CREB coactivator Crtc2 increases insulin sensitivity. Proc Natl Acad Sci U S A (2010) 1.60
WHITE COLLAR-1, a multifunctional neurospora protein involved in the circadian feedback loops, light sensing, and transcription repression of wc-2. J Biol Chem (2002) 1.59
Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet (2010) 1.57
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med (2015) 1.56
Change in knee cartilage T2 at MR imaging after running: a feasibility study. Radiology (2004) 1.56
Regulation of the Neurospora circadian clock by casein kinase II. Genes Dev (2002) 1.56
Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol (2009) 1.55
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther (2009) 1.54